Dogan, Ebru ApaydinGenc, EmineGenc, Bulent OguzErdogan, Cagla2024-02-232024-02-2320171525-50501525-5069https://doi.org/10.1016/j.yebeh.2017.08.040https://hdl.handle.net/20.500.12452/12675Objective: The objective of this study was to evaluate the efficacy, tolerability, and retention rates for zonisamide (ZNS) in older adult patients with focal-onset epilepsy. Patients and methods: Chart reviews of patients aged 60 years and older with focal-onset epilepsy treated with ZNS in two tertiary epilepsy centers were analyzed retrospectively. Results: Eighty-five patients (41 males, 44 females) aged over 60 years (range: 60-81) with focal-onset epilepsy treated with ZNS were identified; 55.3% of the patients (n = 47) were on monotherapy. The median and average doses of ZNS doses were 200 mg/day (range: 100-400) and 212.9 +/- 84.2 mg/day, respectively. With ZNS treatment, 67.1% of the patients (n = 57) were seizure-free for a median of 28 months (range: 10-56) whereas 20% (n = 17) of the patients had seizures that were unresponsive to ZNS treatment. Best seizure control was achieved in patients with poststroke epilepsy; seizure freedom was 80% in this subgroup. Overall retention rate was found to be 83.5%. There was no significant relation between receiving poly- or monotherapy and discontinuation of ZNS (p = 0.18). Thirty-two of the patients (37.6%) lost weight. Median weight loss was 8 kg (range: 2-16). There was no significant correlation between weight loss and the administered doses of ZNS (r = 0.34; p = 0.12). Conclusion: Despite limitations due to the retrospective design of the study, the results show that ZNS is a well-retained drug with high efficacy in older adult patients with epilepsy. (C) 2017 Elsevier Inc. All rights reserved.eninfo:eu-repo/semantics/closedAccessOlder AdultsFocal-Onset EpilepsyZonisamideArticle761923289277112-s2.0-85029517409Q2WOS:000416358200004Q210.1016/j.yebeh.2017.08.040